Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kouichi Yamamura"'
Autor:
Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 15, Iss 12, Pp 987-993 (2024)
Abstract Background Pemetrexed (PEM) is the primary chemotherapy for non‐small cell lung cancer (NSCLC), showing potential for long‐term disease stability in certain cases. However, studies examining disease control with PEM therapy are lacking.
Externí odkaz:
https://doaj.org/article/6fc1ea41a0b142279a109622e0964639
Autor:
Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 36, Pp 3549-3555 (2023)
Abstract Background Several options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are
Externí odkaz:
https://doaj.org/article/3dfcc8af26d449629347ab88334f53e4
Autor:
Yutaka Takahara, Ryudai Abe, Nagae Sumito, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2754-2760 (2023)
Abstract Background Immune checkpoint inhibitor (ICI) monotherapy is currently approved for the treatment of advanced non‐small cell lung cancer (NSCLC) patients with programmed death ligand‐1 (PD‐L1) expression ≥50%. However, the efficacy of
Externí odkaz:
https://doaj.org/article/a909f4025c2145fc8914aa045dfc6961
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno
Publikováno v:
Thoracic Cancer, Vol 14, Iss 14, Pp 1286-1293 (2023)
Abstract Background Amrubicin (AMR) has become the standard of care for post‐relapse small cell lung cancer (SCLC). It has also been reported to achieve long‐term disease control in patients with good treatment response. However, the optimal pati
Externí odkaz:
https://doaj.org/article/99ed1c0dd4b14c28b5532ac4338190f1
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno
Publikováno v:
Thoracic Cancer, Vol 13, Iss 24, Pp 3451-3458 (2022)
Abstract Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC) who receive concu
Externí odkaz:
https://doaj.org/article/bdb7c18e454343c4adf578a932fafbac
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Yuki Fujimoto, Taku Oikawa, Shiro Mizuno
Publikováno v:
Thoracic Cancer, Vol 13, Iss 4, Pp 624-630 (2022)
Abstract Background The efficacy of rechallenge with immune checkpoint inhibitors (ICIs) in non‐small cell lung cancer (NSCLC) patients has not yet been fully clarified. This study aimed to identify the clinical characteristics of patients with NSC
Externí odkaz:
https://doaj.org/article/067210945ff64d138e15835a689a5cea
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno
Publikováno v:
Cancer Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background Large cell neuroendocrine tumors of the lung (LCNEC) are rare. Chemotherapy with the small cell lung carcinoma (SCLC) regimen is the most appropriate treatment for LCNEC. However, there is evidence that the non‐small cell lung c
Externí odkaz:
https://doaj.org/article/34a3bad35bcb43a98a2a400bc4726f5e
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Yuki Fujimoto, Taku Oikawa, Shiro Mizuno
Publikováno v:
Thoracic Cancer, Vol 12, Iss 20, Pp 2758-2766 (2021)
Abstract Background The risk of cancer treatment‐related acute exacerbation (AE) in patients with lung cancer and mild interstitial lung disease (ILD) on imaging, classified as indeterminate for usual interstitial pneumonia (UIP), has not previousl
Externí odkaz:
https://doaj.org/article/c825ca74e7f74b649915839affcb28d3
First case of lung cancer with pneumoconiosis and endobronchial leiomyoma complicating the diagnosis
Autor:
Yutaka Takahara, Kouichi Yamamura, Nozomu Motono, Taku Oikawa, Hidetaka Uramoto, Shiro Mizuno
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background In the treatment of lung cancer, the presence or absence of mediastinal lymph node involvement has a significant bearing on the indication for surgery. In addition, if a tumor is found in the trachea during preoperative scrutiny o
Externí odkaz:
https://doaj.org/article/a87cd9270210420395b932b824d5e4ff
Autor:
Yutaka Takahara, Kouichi Yamamura, Saki Matsuura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Rieko Oikawa, Yuki Fujimoto, Taku Oikawa, Kazuhiro Osanai, Yoshimichi Ueda, Shiro Mizuno
Publikováno v:
Respiratory Medicine Case Reports, Vol 30, Iss , Pp 101124- (2020)
A 53-year-old woman was referred to our hospital for detailed examination of abnormal chest shadows recognized on CT imaging. Transbronchial lung biopsy of a right S6 nodular shadow led to a diagnosis of lung adenocarcinoma. FDG-PET-CT showed FDG acc
Externí odkaz:
https://doaj.org/article/d2e914666e064b0a93cc911c5d2bbd5e